ATOS
Price
$0.89
Change
+$0.01 (+1.14%)
Updated
Jun 27 closing price
Capitalization
115.19M
50 days until earnings call
RGLS
Price
$8.16
Change
+$0.02 (+0.25%)
Updated
Jun 24 closing price
Capitalization
564.95M
44 days until earnings call
Interact to see
Advertisement

ATOS vs RGLS

Header iconATOS vs RGLS Comparison
Open Charts ATOS vs RGLSBanner chart's image
Atossa Therapeutics
Price$0.89
Change+$0.01 (+1.14%)
Volume$16.36M
Capitalization115.19M
Regulus Therapeutics
Price$8.16
Change+$0.02 (+0.25%)
Volume$9.34M
Capitalization564.95M
ATOS vs RGLS Comparison Chart in %
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. RGLS commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Buy and RGLS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ATOS: $0.89 vs. RGLS: $8.16)
Brand notoriety: ATOS and RGLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 1519% vs. RGLS: 300%
Market capitalization -- ATOS: $115.19M vs. RGLS: $564.95M
ATOS [@Biotechnology] is valued at $115.19M. RGLS’s [@Biotechnology] market capitalization is $564.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileRGLS’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • RGLS’s FA Score: 0 green, 5 red.
According to our system of comparison, ATOS is a better buy in the long-term than RGLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 6 TA indicator(s) are bullish while RGLS’s TA Score has 3 bullish TA indicator(s).

  • ATOS’s TA Score: 6 bullish, 1 bearish.
  • RGLS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ATOS is a better buy in the short-term than RGLS.

Price Growth

ATOS (@Biotechnology) experienced а +12.89% price change this week, while RGLS (@Biotechnology) price change was +3.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ATOS is expected to report earnings on Aug 18, 2025.

RGLS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGLS($565M) has a higher market cap than ATOS($115M). RGLS YTD gains are higher at: 416.456 vs. ATOS (-5.540). ATOS has higher annual earnings (EBITDA): -28.04M vs. RGLS (-47.08M). RGLS (65.4M) and ATOS (65.1M) have equal amount of cash in the bank . ATOS has less debt than RGLS: ATOS (0) vs RGLS (1.4M). ATOS (0) and RGLS (0) have equivalent revenues.
ATOSRGLSATOS / RGLS
Capitalization115M565M20%
EBITDA-28.04M-47.08M60%
Gain YTD-5.540416.456-1%
P/E RatioN/AN/A-
Revenue00-
Total Cash65.1M65.4M100%
Total Debt01.4M-
FUNDAMENTALS RATINGS
ATOS vs RGLS: Fundamental Ratings
ATOS
RGLS
OUTLOOK RATING
1..100
4350
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5034
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (28) in the Medical Specialties industry is in the same range as RGLS (60) in the Pharmaceuticals Other industry. This means that ATOS’s stock grew similarly to RGLS’s over the last 12 months.

RGLS's Profit vs Risk Rating (98) in the Pharmaceuticals Other industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that RGLS’s stock grew similarly to ATOS’s over the last 12 months.

RGLS's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as ATOS (97) in the Medical Specialties industry. This means that RGLS’s stock grew similarly to ATOS’s over the last 12 months.

RGLS's Price Growth Rating (34) in the Pharmaceuticals Other industry is in the same range as ATOS (50) in the Medical Specialties industry. This means that RGLS’s stock grew similarly to ATOS’s over the last 12 months.

RGLS's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that RGLS’s stock grew similarly to ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSRGLS
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
72%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 14 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
Bearish Trend 18 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EBKOF85.372.85
+3.45%
Erste Group Bank AG
AMIVF8.460.20
+2.38%
Atrium Mortgage Investment Corp
HMLPF17.00N/A
N/A
Hoegh LNG Partners LP
HBUV1.30N/A
N/A
Hubilu Venture Corporation
STLJF56.71N/A
N/A
Stella Jones Inc.

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
+1.64%
ABOS - ATOS
46%
Loosely correlated
-7.44%
GBIO - ATOS
44%
Loosely correlated
-15.40%
IMNM - ATOS
43%
Loosely correlated
-0.23%
MGNX - ATOS
43%
Loosely correlated
-6.30%
NRIX - ATOS
43%
Loosely correlated
+0.17%
More

RGLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGLS has been loosely correlated with ABEO. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if RGLS jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
N/A
ABEO - RGLS
44%
Loosely correlated
-2.54%
ATOS - RGLS
33%
Poorly correlated
+1.64%
NAUT - RGLS
31%
Poorly correlated
-12.57%
NKTX - RGLS
31%
Poorly correlated
-3.18%
XENE - RGLS
30%
Poorly correlated
+0.62%
More